Bicycle Therapeutics is riding high on the findings of a study published in the February 15 issue of Cancer Research. Results suggest the company's proprietary bicyclic peptide platform is a potentially valuable therapeutic tool for molecular imaging and diagnostics.
The fully synthetic short peptides, known as Bicycles, could become effective agents for molecular imaging to help choose the most appropriate targeted therapy and to monitor patients' responses to treatment, according to the company. The research was conducted in collaboration with the German Cancer Research Center (DKFZ).
The firm is developing Bicycles for the treatment of cancer, as well as in collaboration with others for therapeutic areas that could include respiratory, cardiovascular, hematology, and infectious diseases.